Nanofat Grafting as a Method of Treating Critical Limb Ischemia

Status Not yet recruiting

Clinical Trial Summary

This clinical trial will investigate nano fat grafting as a method for treating critical limb ischemia. The method involves the collection of adipose tissue under tumescent anesthesia through a separate incision in the anterior abdominal wall, followed by preparation and injection of nano fat into the tissues of the foot and leg without additional drug therapy. The novelty of this method lies in the use of autologous stem cells and growth factors, differing from current treatments like neovasculgen, which is a plasmid DNA-based treatment. The trial aims to assess the safety and effectiveness of nano fat grafting, including pain relief, the frequency of intraoperative complications, increased distance of pain-free walking, limb preservation, and mortality rates. The trial will involve patients with diagnosed occlusive lesions of the femoral-popliteal-tibial segment and chronic ischemia of III-IV degree according to Fontaine and 5-6 categories according to Rutherford, excluding those with contraindications for surgical intervention on the femoral-popliteal-tibial segment, chronic heart failure of III-IV NYHA class, severe liver or kidney failure, among others. The study design includes preoperative examinations, hospital phase activities including the surgery and post-operative assessments, and follow-up visits at 6 and 12 months post-operation to evaluate the method's safety, complications, and effectiveness based on various parameters like pain, trophic disturbances, and limb ischemia severity. Statistical methods will involve quantitative data presented as mean ± standard deviation, with qualitative traits compared using the Chi-square test or Fisher's exact test. The planned patient number is 40, aiming to demonstrate the effectiveness and safety of nano fat grafting for critical limb ischemia treatment compared to current treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Limb-Threatening Ischemia
Ischemia
Limb Ischemia

Clinical Trial Details

NCT number	NCT06357936
Study type	Interventional
Source	Center of New Medical Technologies
Contact	Andrey V Ponomarenko, MD
Phone	+79628316017
Email	ponomarenko_av@cnmt.ru
Status	Not yet recruiting
Phase	N/A
Start date	April 20, 2024
Completion date	February 20, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05411315` - Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment	N/A
Completed	`NCT04066387` - Characteristics and Prognosis of Patients With Critical Ischemia at High Risk of Amputation Managed by Endovascular Bypass: a Retrospective Study of 15 Patients
Completed	`NCT00453531` - Model System for Transient Forearm Blood Vessel Dysfunction	Phase 1/Phase 2
Completed	`NCT00730561` - Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy	N/A
Completed	`NCT05410548` - Comorbidity Screening and Referral by Prosthetists	N/A
Enrolling by invitation	`NCT06229015` - Evaluation of Online Tool (E-TOOL SCS) in Spinal Cord Stimulaion
Recruiting	`NCT05830721` - Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients	N/A
Completed	`NCT04016857` - Remote Ischemic Preconditioning During Lower Limb Revascularization	N/A
Active, not recruiting	`NCT04466007` - Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia	Phase 2
Recruiting	`NCT06050499` - Chemical Analysis of Limb Microfluidics
Not yet recruiting	`NCT04622878` - Combined Management in ALI ( Image Guided Thrombectomy With Open Transfemoral Access )	N/A
Recruiting	`NCT03040063` - Complex Endovascular Approach to Treatment of Patients With Aneurysm of Popliteal Artery	N/A
Completed	`NCT04343196` - Digital Variance Angiography in Diagnostic Angiographies for Effective Radiation Dose Reduction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.